

# 223 - References

## References

222 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 Other options include adding pimozide, olanzapine or sertindole. None is recommended: pimozide and sertindole have important cardiac toxicity and the addition of olanzapine is poorly supported<sup>96</sup> and likely to exacerbate metabolic adverse effects. Studies of pimozide<sup>97,98</sup> and sertindole<sup>99</sup> have shown no effect. One small RCT supports the use of Ginkgo biloba<sup>100</sup> and another two support the use of memantine.<sup>101,102</sup> Another study suggests possible benefit of augmentation with acetyl-L-carnitine<sup>103</sup> and a case study reports good outcome with thyroxine.<sup>104</sup> A single RCT describes successful use of sodium benzoate.<sup>105</sup> Minocycline is probably not effective.<sup>77,106</sup> Glycine may be effective for positive symptoms, but studies are of poor quality.<sup>107</sup> A small case series (n = 6) found benefit from adding pimavanserin.<sup>108</sup> N-acetylcysteine is probably of no benefit.<sup>109–111</sup>

References

1. Taylor D, et al. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. *Int J Psychiatry Clin Pract* 2000; 4:41–46.
2. Murphy B, et al. Maintenance doses for clozapine. *Psychiatr Bull* 1998; 22:12–14.
3. Taylor D. Pharmacokinetic interactions involving clozapine. *Br J Psychiatry* 1997; 171:109–112.
4. Lane HY, et al. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. *J Clin Psychiatry* 1999; 60:36–40.
5. Taylor D, et al. Predicting clozapine dose required to achieve a therapeutic plasma concentration: a comparison of a population algorithm and three algorithms based on gene variant models. *J Psychopharmacol* 2023; 37:1030–1039.
6. Taylor D, et al. The use of clozapine plasma levels in optimising therapy. *Psychiatr Bull* 1995; 19:753–755.
7. Spina E, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. *Psychopharmacology* 2000; 148:83–89.
8. Perry PJ. Therapeutic drug monitoring of antipsychotics. *Psychopharmacol Bull* 2001; 35:19–29.
9. Kronig MH, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. *Am J Psychiatry* 1995; 152:179–182.
10. Polcwiartek C, et al. The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. *Psychopharmacology (Berl)* 2016; 233:741–750.
11. Leising J, et al. High-dose fluvoxamine augmentation to clozapine in treatment-resistant psychosis. *J Clin Psychopharmacol* 2021; 41:186–190.

12. Watras M, et al. A therapeutic interaction between cimetidine and clozapine: case study and review of the literature. *Ther Adv Psychopharmacol* 2013; 3:294–297.
13. Gee S, et al. Optimising treatment of schizophrenia: the role of adjunctive fluvoxamine. *Psychopharmacology (Berl)* 2016; 233:739–740.
14. Schoretsanitis G, et al. A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. *Expert Rev Clin Pharmacol* 2019; 12:603–621.
15. Chakrabarti S. Clozapine resistant schizophrenia: newer avenues of management. *World J Psychiatry* 2021; 11:429–448.
16. Etchecopar-Etchart D, et al. Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis. *EClinicalMedicine* 2024; 69:102473.
17. Mishra A, et al. Augmentation strategies for partial or non-responders to clozapine in patients with schizophrenia: a Bayesian network meta- analysis of randomized controlled trials. *Clin Psychopharmacol Neurosci* 2024; 22:232–252.
18. Grover S, et al. Augmentation strategies for clozapine resistance: a systematic review and meta-analysis. *Acta Neuropsychiatr* 2023; 35:65–75.
19. Yeh TC, et al. Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: a systematic review and network meta-analysis with normalized entropy assessment. *Asian J Psychiatr* 2023; 79:103375.
20. Barbui C, et al. Does the addition of a second antipsychotic drug improve clozapine treatment? *Schizophr Bull* 2009; 35:458–468.
21. Paton C, et al. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. *J Clin Psychopharmacol* 2007; 27:198–204.
22. Taylor D, et al. Augmentation of clozapine with a second antipsychotic: a meta analysis. *Acta Psychiatr Scand* 2012; 125:15–24.
23. Bartoli F, et al. Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: a meta- analysis. *J Psychiatr Res* 2019; 108:24–33.
24. Wagner E, et al. Clozapine combination and augmentation strategies in patients with schizophrenia: recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) working group. *Schizophr Bull* 2020; 46:1459–1470.
25. Demjaha A, et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. *Am J Psychiatry* 2012; 169:1203–1210.
26. Demjaha A, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. *Biol Psychiatry* 2014; 75:e11–e13.
27. Fleischhacker WW, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. *Int J Neuropsychopharmacol* 2010; 13:1115–1125.
28. Correll CU, et al. Selective effects of individual antipsychotic cotreatments on cardiometabolic and hormonal risk status: results from a systematic review and meta-analysis. *Schizophr Bull* 2013; 39 Suppl 1:S29–S30.

Schizophrenia and related psychoses CHAPTER 1 29. Oloyede E, et al. Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review. *Ther Adv*

Psychopharmacol 2022; 12:20451253211066642. 30. Berardis D, et al. Cariprazine add-on in inadequate clozapine response: a report on two cases. Clin Psychopharmacol Neurosci 2021; 19:174–178. 31. Pappa S, et al. Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study. Ther Adv Psychopharmacol 2022; 12:20451253221132087. 32. Siwek M, et al. Cariprazine augmentation of clozapine in schizophrenia—a retrospective chart review. Front Pharmacol 2024; 14:1321112. 33. Matthiasson P, et al. Relationship between dopamine D2 receptor occupancy and clinical response in amisulpride augmentation of clozapine non-response. J Psychopharmacol 2001; 15:S41. 34. Munro J, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004; 110:292–298. 35. Zink M, et al. Combination of clozapine and amisulpride in treatment-resistant schizophrenia: case reports and review of the literature. Pharmacopsychiatry 2004; 37:26–31. 36. Ziegenbein M, et al. Augmentation of clozapine with amisulpride in patients with treatment-resistant schizophrenia: an open clinical study. German J Psychiatry 2006; 9:17–21. 37. Kampf P, et al. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry 2005; 38:39–40. 38. Assion HJ, et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine: a randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008; 41:24–28. 39. Poonia S, et al. Amisulpride augmentation of clozapine in clozapine-resistant schizophrenia: a case series. Can J Hosp Pharm 2022; 75:234–238. 40. Zhu MH, et al. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. Mil Med Res 2022; 9:59. 41. Barnes TR, et al. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health Technol Assess 2017; 21:1–56. 42. Barnes TRE, et al. Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial. Ther Adv Psychopharmacol 2018; 8:185–197. 43. Croissant B, et al. Reduction of side effects by combining clozapine with amisulpride: case report and short review of clozapine-induced hypersalivation – a case report. Pharmacopsychiatry 2005; 38:38–39. 44. Oloyede E, et al. Clozapine augmentation with long-acting antipsychotic injections: a case series and systematic review. Acta Psychiatr Scand 2023; 148:538–552. 45. Joo SW, et al. Comparative effectiveness of antipsychotic monotherapy and polypharmacy in schizophrenia patients with clozapine treatment: a nationwide, health insurance data-based study. Eur Neuropsychopharmacol 2022; 59:36–44. 46. Nováková M, et al. Potential impact on mental health in patients with treatment-resistant schizophrenia: clozapine augmentation with long-acting parenteral antipsychotics: a case series. Ceska Slov Farm 2024; 72:277–287. 47. Mukherjee H, et al. Predictors of functioning and clinical outcomes in inpatient with schizophrenia on clozapine augmented with antipsychotics. Australas Psychiatry 2022; 30:100–104. 48. Bioque M, et al. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: a retrospective 6-month mirror-image study. Eur Psychiatry 2020; 63:e71. 49. Chang JS, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69:720–731. 50. Muscatello MR, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res 2011; 127:93–99. 51. Cipriani A, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. J Clin Psychopharmacol 2013; 33:533–537. 52. Tiihonen J, et al. Association of antipsychotic polypharmacy vs monotherapy with

psychiatric rehospitalization among adults with schizophrenia. *JAMA Psychiatry* 2019; 76:499–507.

53. Srisurapanont M, et al. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. *J Psychiatr Res* 2015; 62:38–47.

54. Balcioglu YH, et al. One plus one sometimes equals more than two: long-acting injectable aripiprazole adjunction in clozapine-resistant schizophrenia. *Clin Neuropharmacol* 2020; 43:166–168.

55. Grimminck R, et al. Combination of clozapine with long-acting injectable antipsychotics in treatment-resistant schizophrenia: preliminary evidence from health care utilization indices. *Prim Care Companion CNS Disord* 2020; 22:19m02560.

56. Karoline RD, et al. Cariprazine augmentation in a patient with clozapine-resistant schizophrenia. *Ind Psychiatry J* 2023; 32:S279–S280.

57. Weise J, et al. Add-on cariprazine in patients with long-term clozapine treatment and treatment resistant schizophrenia: two cases of psychotic deterioration and Pisa syndrome. *Clin Psychopharmacol Neurosci* 2022; 20:398–401.

58. Rajarethinam R, et al. Augmentation of clozapine partial responders with conventional antipsychotics. *Schizophr Res* 2003; 60:97–98.

59. Barbui C, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. *J Clin Psychopharmacol* 2011; 31:266–273.

60. Dursun SM, et al. Clozapine plus lamotrigine in treatment-resistant schizophrenia. *Arch Gen Psychiatry* 1999; 56:950.

61. Dursun SM, et al. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. *J Psychopharmacol* 2001; 15:297–301.

224 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1

62. Tiihonen J, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. *Biol Psychiatry* 2003; 54:1241–1248.

63. Kalyoncu A, et al. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? *J Psychopharmacol* 2005; 19:301–305.

64. Goff DC, et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. *J Clin Psychopharmacol* 2007; 27:582–589.

65. Heck AH, et al. Addition of lamotrigine to clozapine in inpatients with chronic psychosis. *J Clin Psychiatry* 2005; 66:1333.

66. Vayisoglu S, et al. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. *Schizophr Res* 2013; 143:207–214.

67. Tiihonen J, et al. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. *Schizophr Res* 2009; 109:10–14.

68. Zheng W, et al. Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials. *J Clin Psychiatry* 2017; 78:e498–e505.

69. Olivola M, et al. Lurasidone augmentation of clozapine in refractory schizophrenia: a case series. *J Clin Psychopharmacol* 2023; 43:157–160.

70. Peet M, et al. Double-blind placebo controlled trial of N-3 polyunsaturated fatty acids as an adjunct to neuroleptics. *Schizophr Res* 1998; 29:160–161.

71. Puri BK, et al. Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid. *Arch Gen Psychiatry* 1998; 55:188–189.

72. Josiassen RC, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. *Am J Psychiatry* 2005; 162:130–136.

73. Raskin S, et al. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. *Acta Psychiatr Scand* 2000; 101:334–336.

74. Anil Yagcioglu AE, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. *J Clin Psychiatry* 2005; 66:63–72.

75. Honer WG, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. *N Engl J Med* 2006; 354:472–482.

76. Se HK, et al. The combined use of risperidone long-acting injection

and clozapine in patients with schizophrenia non-adherent to clozapine: a case series. *J Psychopharmacol* 2010; 24:981–986. 77. Siskind DJ, et al. Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. *Aust N Z J Psychiatry* 2018; 52:751–767. 78. Wang Y, et al. Valproate for schizophrenia. *Cochrane Database Syst Rev* 2016; 11:CD004028. 79. Shiloh R, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. *Br J Psychiatry* 1997; 171:569–573. 80. Wang J, et al. Sulpiride augmentation for schizophrenia. *Schizophr Bull* 2010; 36:229–230. 81. Tiihonen J, et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. *J Clin Psychiatry* 2005; 66:1012–1015. 82. Afshar H, et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. *J Psychopharmacol* 2009; 23:157–162. 83. Muscatello MR, et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. *J Psychopharmacol* 2011; 25:667–674. 84. Hahn MK, et al. Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. *J Clin Psychopharmacol* 2010; 30:706–710. 85. Behdani F, et al. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial. *Arch Iran Med* 2011; 14:270–275. 86. Millson RC, et al. Topiramate for refractory schizophrenia. *Am J Psychiatry* 2002; 159:675. 87. Zheng W, et al. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. *Acta Psychiatr Scand* 2016; 134:385–398. 88. Zink M, et al. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia. *Hum Psychopharmacol* 2004; 19:271–273. 89. Ziegenbein M, et al. Clozapine and ziprasidone: a useful combination in patients with treatment-resistant schizophrenia. *J Neuropsychiatry Clin Neurosci* 2006; 18:246–247. 90. Ziegenbein M, et al. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. *Clin Neuropharmacol* 2005; 28:220–224. 91. Zink M, et al. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. *J Psychopharmacol* 2009; 23:305–314. 92. Muscatello MR, et al. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study. *J Clin Psychopharmacol* 2014; 34:129–133. 93. Citrome L. Schizophrenia and valproate. *Psychopharmacol Bull* 2003; 37 Suppl 2:74–88. 94. Tranulis C, et al. Somatic augmentation strategies in clozapine resistance: what facts? *Clin Neuropharmacol* 2006; 29:34–44. 95. Suzuki T, et al. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. *Hum Psychopharmacol* 2009; 24:628–638. 96. Gupta S, et al. Olanzapine augmentation of clozapine. *Ann Clin Psychiatry* 1998; 10:113–115. 97. Friedman JI, et al. Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. *Neuropsychopharmacology* 2011; 36:1289–1295.

Schizophrenia and related psychoses CHAPTER 1 98. Gunduz-Bruce H, et al. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. *Schizophr Res* 2013; 143:344–347. 99. Nielsen J, et al. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study. *J Clin Psychopharmacol* 2012; 32:173–178. 100. Doruk A, et al. A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. *Int Clin Psychopharmacol* 2008; 23:223–227. 101. de Lucena D, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. *J Clin Psychiatry* 2009; 70:1416–1423. 102. Veerman SR, et al. Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. *Psychol Med* 2017;

47:363–375. 103. Bruno A, et al. Acetyl-L-carnitine augmentation of clozapine in partial-responder schizophrenia: a 12-week, open-label uncontrolled preliminary study. *Clin Neuropharmacol* 2016; 39:277–280. 104. Seddigh R, et al. Levothyroxine augmentation in clozapine resistant schizophrenia: a case report and review. *Case Rep Psychiatry* 2015; 2015:678040. 105. Lin CH, et al. Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. *Biol Psychiatry* 2018; 84:422–432. 106. Kelly DL, et al. Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. *J Clin Psychopharmacol* 2015; 35:374–381. 107. Correll CU, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. *JAMA Psychiatry* 2017; 74:675–684. 108. Nasrallah HA, et al. Successful treatment of clozapine--nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. *Schizophr Res* 2019; 208:217–220. 109. Yolland CO, et al. Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia. *Aust N Z J Psychiatry* 2020; 54:453–466. 110. Neill E, et al. N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double-blind, randomized, placebo-controlled trial targeting negative symptoms. *Schizophr Bull* 2022; 48:1263–1272. 111. Andrade C. Antipsychotic augmentation with N-acetylcysteine for patients with schizophrenia. *J Clin Psychiatry* 2022; 83:22f14664.

---

Revision #1

Created 2026-01-04 20:13:17 UTC by Omar Ayman

Updated 2026-01-04 20:13:17 UTC by Omar Ayman